US pharmaceutical firm Johnson & Johnson might submit an official utility for its vaccine in opposition to COVID-19 to the European Medicines Agency (EMA) in February, in keeping with the bloc’s Health chief, Stella Kyriakides.
While the approval of jab developed by J&J might mark the EU’s fourth COVID-19 vaccine, it’s “vaccinations” and never the vaccine itself that may save lives, Kyriakides stated, Reuters reported, citing Peter Liese, an EU lawmakers who speaks on well being issues for the European People’s Party (EPP).
The Commission’s take care of Johnson & Johnson was inked in October, underneath which, its subsidiary Janssen Pharmaceutica NV might provide the EU with as much as 400 million doses of its COVID-19 vaccine.
Once the vaccine will get the green-light by regulators, the American pharmaceutical might allocate 200 million doses of the potential vaccine, ranging from mid-2021, with the likelihood to safe an extra 200 million doses.
An EU official instructed Reuters that Johnson & Johnson might ship the primary doses of its COVID-19 vaccine to Europe on April 1, whereas a spokesperson of Kyriakides stated the Commission can not give “any precise indications regarding an application for conditional marketing authorisation, but we of course hope that an application could be submitted in the coming weeks.”